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Objectives: Cell therapy improved cardiac function after a myocardial infarction in several preclinical studies;
however, the functional benefits were limited in the initial clinical trials, perhaps because of inadequate cell en-
graftment. We used noninvasive molecular imaging to compare the distribution and myocardial retention of cells
implanted by using clinical delivery routes.
Methods: Bone marrow stromal cells isolated from male rats and transfected with a firefly luciferase reporter
gene were injected by using 3 increasingly invasive techniques (ie, intravenous, intra-aortic, and intramyocardial)
into female rats 3 or 28 days after coronary ligation. Whole-body bioluminescence imaging was performed 2, 24,
and 48 hours later; implanted cells were quantified at 48 hours in explanted organs by means of bioluminescence
and real-time polymerase chain reaction.
Results: Variations in cell distribution among groups were profound, with nearly complete trapping of the in-
jected cells in the lungs after intravenous delivery. Cell delivery into the aortic root (with the distal aorta occluded)
produced minimal cell retention in the heart. Direct intramyocardial injection facilitated the best early targeting of
the cells (P< .05 vs intravenous and intra-aortic injection). Rapid signal loss over 48 hours indicated very poor
cell survival in all 3 groups, although implanted cell retention was greater in mature compared with acute infarcts.
Conclusions: This is the first study to correlate live cell imaging with quantitative genetic and histologic tech-
niques. Noninvasive molecular imaging tracked delivered cells and will permit the evaluation of new and
improved delivery platforms designed to increase cell homing, retention, and engraftment.
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Cell implantation improves cardiac function after a myocar-
dial infarction (MI) in animal studies1-5; however, the initial
clinical trials did not provide the same benefit.6-9 Similarly,
cell therapy as an adjunct to coronary bypass surgery pro-
duced mixed effects on ventricular function in patients
with postinfarction dysfunction.10,11 Contributing to these
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which determine implanted cell homing, retention, and ex-
tent of engraftment within the damaged myocardium. Low
survival rates among implanted cells, as assessed by preclin-
ical and clinical trials, have emphasized the necessity for
new approaches to enhance cell engraftment.
Although the quantification of cell survival traditionally
relies on postmortem histology, molecular imaging provides
an improved opportunity to evaluate new techniques by es-
timating in vivo survival and engraftment of live cells. In the
current study we used a molecular imaging technique to
track implanted cells for 48 hours after implantation.12-15
Our results provide the first comprehensive comparison of
live cell imaging and histologic evidence of postimplanta-
tion cell distribution.
Bone marrow stromal cells (BMSCs) injected into the
myocardium can engraft in the damaged heart, induce angio-
genesis and matrix remodeling, and improve ventricular
function.16,17 Here, BMSCs transfected with a firefly lucifer-
ase (FL) reporter gene were implanted into rats either early
or late after an MI by using 3 clinically relevant delivery
routes: intra-aortic (cells injected into the aortic root with
the distal aorta temporarily occluded to simulate intracoro-
nary delivery), intravenous, or intramyocardial. After im-
plantation, FL is only expressed by live cells. Each living
cell with active FL generates a measurable signal in vivo
by converting a systemically injected substrate (luciferin)rdiovascular Surgery c Volume 137, Number 5 1225
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SAbbreviations and Acronyms
Ad-CMV-FL ¼ firefly luciferase reporter gene
driven by a constitutive
cytomegalovirus promoter
BMSC ¼ bone marrow stromal cell
FL ¼ firefly luciferase
LAD ¼ left anterior descending
coronary artery
MI ¼ myocardial infarction
MOI ¼ multiplicity of infection
PCR ¼ polymerase chain reaction
to produce photons that can be recorded with a biolumines-
cent camera and quantified. In contrast, no bioluminescent
signals are generated by dead or metabolically inactive (hi-
bernating) cells that cannot convert the substrate.
MATERIALS AND METHODS
Experimental Animals
BMSCs were isolated from male Lewis rats for implantation into female
recipients. The Animal Care Committee of the Toronto General Research
Institute approved all experimental procedures, which were in accordance
with the National Research Council’s ‘‘Guide for the care and use of labo-
ratory animals’’ (revised 1996).
Virus Construction and Amplification
Replication-defective recombinant adenovirus carrying the FL reporter
gene driven by a constitutive cytomegalovirus promoter (Ad-CMV-FL)
was purchased from Vector Biolabs (Philadelphia, Pa). The viral vector was
amplified with AD 293 cells. The titer of the viral stock (supernatant) was
determined by using a plaque assay with agarose overlay.
Cell Culture, Transfection, and In Vitro Assay for FL
Activity
Male Lewis rat BMSCs (10–20 mm in diameter, as shown in Figure 1)
were cultured18,19 and transfected with Ad-CMV-FL at multiplicity of infec-
tion (MOI) 10 and 50 for 24 hours. Luciferase assays (BD Biosciences, Mis-
sissauga, Ontario, Canada) were performed on days 1, 2, 3, 6, and 7 after
viral vector transfection, according to the manufacturer’s instructions, to
confirm reporter enzyme activity before cell transplantation.
Myocardial Infarction and Cell Transplantation
Female rats were anesthetized with isoflurane (2%) during mechanical
ventilation. MI was induced through a thoracotomy by means of occlusion
of the left anterior descending coronary artery (LAD). Animals were ran-
domly separated into 6 groups. Rats in each group received 3 3 106 trans-
fected BMSCs in 100 mL of serum-free medium at 1 of 2 time points (ie, 3
or 28 days after LAD ligation [LAD3 and LAD28, respectively]) delivered
through 1 of 3 routes: intra-aortic, intravenous, or intramyocardial injec-
tion. Procedures are detailed in the online-only Materials and Methods sec-
tion. Three additional groups without LAD ligation (sham controls) also
received BMSCs by means of intra-aortic, intravenous, or intramyocardial
injection. Therefore cells were delivered to animals in the control, LAD3,
and LAD28 groups through 3 different injection routes (ie, intra-aortic,
intravenous, and intramyocardial) for a total of 9 groups (see schematic
in Figure 2, A).1226 The Journal of Thoracic and Cardiovascular SOptical Bioluminescence Imaging
At 2, 24, and 48 hours after cell implantation, all rats received an in-
traperitoneal injection of the FL reporter substrate luciferin (D-luciferin,
375 mg/kg body weight; Xenogen Corp, Hopkinton, Mass). Live cells
expressing the FL enzyme (dead or metabolically inactive cells cannot
express FL in vivo) converted the luciferin to inactive oxyluciferin, pro-
ducing photons that were captured by a charged-coupled device camera
system (IVIS, Xenogen Corp). Bioluminescence (generated by viable,
metabolically active cells) was quantified in photons per second per
square centimeter per steradian. Whole-body imaging was performed for
each animal at 48 hours, followed immediately by imaging of explanted
organs.
Genomic Real-Time Polymerase Chain Reaction
Male rat BMSCs were used to generate a standard curve with Y chromo-
some copies of 105, 104, 103, 102, and 101 by using specific primers, as pre-
viously described in detail.17 Genomic DNA was extracted from excised,
homogenized tissues (heart, liver, spleen, kidney and lungs), and Y chromo-
somes were detected (TaqMan method). The atria and great vessels were re-
moved from the excised hearts before DNA extraction; only the ventricles
were included in the analysis.
Immunohistochemistry
Serial cryosections were stained with a monoclonal anti-luciferase anti-
body (Santa Cruz Biotechnology, Santa Cruz, Calif) followed by a fluores-
cein isothiocyanate–conjugated secondary antibody (Molecular Probes,
Burlington, Vt) to localize implanted cells. Nuclei were stained with 40-6-
diamidino-2-phenylindole dihydrochloride (Sigma, Oakville, Ontario,
Canada) for in vitro studies or propidium iodide (Sigma) for in vivo studies.
Data Analysis
All data were expressed as means standard error of the mean.Multiple-
group comparisons were performed by using 1-way analysis of variance.
When required, differences were specified by means of post-hoc evaluation
with least-squares difference multiple range tests (SPSS software, version
10.0; SPSS, Inc, Chicago, Ill).
RESULTS
Effect of FL Reporter Gene Expression on BMSC
Viability and Proliferation
Cultured BMSCs were transfected with Ad-CMV-FL at
MOI 10 and MOI 50. We observed no effects of transfection
on cell morphology (Figure 1, A and B) or viability (Trypan
Blue exclusion assay: control, 95.6%  3.4%; MOI 50,
92.9%  1.7%) and no significant effects on cell growth
(Figure 1, C).
Immunohistochemical staining with an anti-luciferase an-
tibody showed that more than 90% of cultured cells were
successfully transfected (Figure 1,D–F). Although FL activ-
ity was increased (compared with undetectable activity in
nontransfected cells) in both groups of transfected BMSCs,
the FL activity was nearly 40-fold higher in cells transfected
at MOI 50 compared with those transfected at MOI 10 (P<
.01; Figure 1, G). MOI 50 cells were used for the in vivo
study. When transfected cells were seeded into culture
dishes at different concentrations, bioluminescence counts
correlated linearly with cell number (r2 ¼ 0.99; Figure 1,
H and I).urgery c May 2009
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(Molecular Imaging)
The whole-body biodistribution of implanted FL-labeled
BMSCswas evaluated in all groups bymeans of biolumines-
cence imaging (Figure 2, B–D). Intra-aortic implantation re-
sulted in diffuse and systemic bioluminescence, with no
differences based on the timing of injection. The total signal
decreased over time (P<.05), indicating a loss of FL expres-
sion likely caused by a decrease in the number of viable
cells. Cell retention (compared with the 2-hour time point)
decreased by 60% at 24 hours and by 90% at 48 hours after
cell implantation. Animals that received intravenous cell im-
plantation exhibited bioluminescence confined to the chest
at all time points. The signals decreased significantly over
time (P< .05), with reductions of 80% (compared with
the 2-hour time point) by 24 hours and 95% by 48 hours af-
ter implantation. In rats that received intramyocardial cell
implantation, bioluminescence was similarly confined to
the chest at all time points, but signals were strongest on
the left side of the chest, suggesting that cells were mainly
localized in the heart. Although bioluminescence decreased
over time (P<.05) in the intramyocardial groups, cell reten-
tion (compared with the 2-hour time point) was between
30% and 75% at 24 hours and remained greater than
25% at 48 hours after implantation.
At 2 hours after cell implantation, total bioluminescence
counts (Figure 2, E–G) were similar among the 3 implanta-
tion routes. At 24 hours, cell retention was lowest when the
cells were injected intravenously (P<.05 compared with the
intra-aortic groups) and highest when the cells were deliv-
ered intramyocardially into either acute or chronic scars.
At 48 hours after implantation, there were no differences
in cell retention between the intra-aortic and intravenous
groups, both of which exhibited significantly less retention
than the intramyocardial groups (P< .05 for all groups).
Whole-body bioluminescence counts were statistically sim-
ilar among groups, irrespective of whether BMSCs were ad-
ministered at LAD3 or LAD28.
Cell Retention in Tissues (Real-Time Polymerase
Chain Reaction and Molecular Imaging)
The heart, liver, spleen, kidney, and lungs were explanted
at 48 hours after cell delivery, imaged immediately by means
of bioluminescence, and then subjected to real-time polymer-
ase chain reaction (PCR) quantification (Figure 3). After
intra-aortic cell injection, bioluminescence appeared to be
distributed primarilywithin the heart, kidney, and lungs (Fig-
ure 3, A and B). When cells were delivered in an intra-aortic
manner into a mature scar (late after the infarct), biolumines-
cence localized predominantly to the heart, with significantly
weaker signals in the remaining organs (P<.05). Consistent
with these results, real-time PCR detected the greatest num-
ber of implanted cells in the heart when the cells were im-The Journal of Thoracic and Cplanted in an intra-aortic manner at 28 days after MI (P<
.05; Figure 3, C). Implanted BMSCs were also detected in
the kidney and lungs, but not in the liver or spleen, by means
of real-time PCR. There was a strong association between re-
sults from bioluminescence imaging and real-time PCR after
intra-aortic injection.
In the groups that received cells through the intravenous
route, both bioluminescence and real-time PCR assays
showed that more than 90% of the surviving cells were
trapped in the lungs (Figure 3, A, D, and E). Again, distribu-
tion patterns obtained with both methods were in very close
agreement.
Intramyocardial injection resulted in bioluminescence
signals localized almost entirely to the heart and lungs,
with significantly weaker (P< .05) signals in the remaining
organs (Figure 3, A and F). Real-time PCR detected cells
only in the heart and lungs (Figure 3, G), with significantly
higher (P< .05) cell retention in the heart than the lungs in
all groups—particularly in animals that received cells at 28
days after MI. Imaging revealed a similar pattern (Figure 3,
F), although the differences between signals from the heart
and lungs did not reach significance.
Implanted Cell Localization
Implanted cells were localized by using immunohisto-
chemical staining with an antibody against luciferase protein
(Figure 4, A). Results were very similar to those from biolu-
minescence imaging and real-time PCR studies. In animals
that received intra-aortic implantation, donor BMSCs were
identified in heart, kidney, and lung tissue, with a few cells
also detected in the liver and spleen. In animals that received
intravenous implantation, many cells strongly positive for
FL were observed in the lungs, with only a few implanted
cells present in the other organs. In animals that received in-
tramyocardial implantation, the greatest numbers of donor
cells were identified in the heart and lungs.
Cardiac Retention of Cells Implanted Into Acute or
Chronic Scars
Data obtained from isolated hearts were compared among
all groups (Figure 4, B–G). Both bioluminescence imaging
and real-time PCR confirmed that maximal cell retention
was achieved with intramyocardial implantation. Regarding
timing of treatment, although delivery at LAD3 and after the
shamoperation (control) consistentlyproduced similar results,
cell retention after intramyocardial injection into a mature
myocardial scar was 6- to 8-fold greater (P< .05) than that
achieved with intramyocardial injection into control myocar-
dium (Figure 4, F and G). Similarly, in the intra-aortic group
we detected significantly more (P< .05) cells in LAD28
animals than in LAD3 or control animals (Figure 4, B and
C). Few cells delivered by means of intravenous injection
were observed in the myocardial tissue (Figure 4, D and E).ardiovascular Surgery c Volume 137, Number 5 1227
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FIGURE 2. In vivo bioluminescence imaging. A, Experimental design. Bone marrow stromal cells transfected with firefly luciferase reporter gene were
implanted (Tx) into rats after sham operation (Control) or at 3 days (LAD3) or 28 days (LAD28) after coronary artery ligation (MI) by means of 1 of 3 routes:
intra-aortic (IA), intravenous (IV), or intramyocardial (IM). Sample sizes for each of the resulting 9 groups are indicated. Whole-body bioluminescence im-
aging (BLI) was performed at 2, 24, and 48 hours after implantation. Imaging of explanted organs and real-time polymerase chain reaction analysis were
performed subsequently at 48 hours. B–D, Representative bioluminescence images obtained at 2, 24, and 48 hours after cell implantation by means of in-
tra-aortic (B), intravenous (C), or intramyocardial (D) injection in control rats (after the sham operation). E–G, Corresponding bioluminescence counts
(BLI) integrated over the whole body after cell implantation at LAD3 or LAD28 or in control animals. N ¼ 4 (LAD3-IA, LAD28-IA, LAD28-IV,
LAD28-IM), n ¼ 5 (Control-IA and Control-IM), and n ¼ 6 (Control-IV, LAD3-IV, LAD3-IM) per group. *P< .05 versus the corresponding intra-aortic
and intravenous groups.DISCUSSION
Although preclinical cell therapy produced promising im-
provements in ventricular function, clinical trials have been
less encouraging. For example, cells (bone marrow and
peripheral stem cells or skeletal myoblasts) injected intrave-
nously and into coronary arteries early or late after anMI6-9 or
into a chronic infarct during coronary bypass surgery in
patients with a nonbypassable region10,11 produced mixed
functional effects. Although the benefits (improved heartThe Journal of Thoracic and Cfunction) and the risks (remote organ engraftment or resteno-
sis) of cell therapy are largely determined by the extent of re-
tention of the implanted cells immediately after injection,
current approaches to track implanted cells (male cell im-
plantation into female recipients, green fluorescent protein
or b-galactosidase gene labeling, and membrane labeling)
exclude the possibility of in vivo cell tracking because they
must be performed at the end of the study. The current study
describes a molecular imaging technique that provides theFIGURE 1. In vitro studies.A andB,Cellmorphology of cultured bonemarrow stromal cells transfectedwith firefly luciferase gene atmultiplicity of infection
(MOI) 50 (A) or vector (B). C, Cell proliferation (cell number) in vector-transfected (Control) or MOI 50 colonies. D–F, Immunohistochemical staining (lu-
ciferase¼ green, D; 40-6-diamidino-2-phenylindole dihydrochloride [DAPI]¼ blue, E) showing luciferase protein expression in the transfected cells (arrows
in D-F). (Original magnification 2003 in D-F.) G, Luciferase activity in cell lysates transfected with viral vector at MOI 10 or 50 for 7 days after transfection.
RLU, relative light units. H and I, Correlation between transfected cell number and luciferase activity (BLI). N ¼ 3 per group in C and G. r2 ¼ 0.99.ardiovascular Surgery c Volume 137, Number 5 1229
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*P< .05 versus the control group in F.opportunity to obtain a clear understanding of implanted cell
fate, which is necessary to improve the clinical outcomes of
cell therapy.
We used noninvasive optical imaging to track and
compare the quantitative distribution of viable BMSCs im-
planted early or late after an MI by each of 3 clinically rele-
vant implantation routes. Within 48 hours of delivery, the
majority of implanted cells were localized in the extracardiac
organs. This widespread nontargeted distribution illustrates
the importance of tracking cell fate after delivery and theThe Journal of Thoracic and Caneed for novel techniques to increase cell retention. This
study is the first to provide a quantitative comparison of
live cell imaging and in vitro assessments of cell retention
(real-time PCR and immunohistochemistry). Correspon-
dence with the other approaches was excellent, but only
imaging permits a serial evaluation in the same animal.
Intracoronary injection is the most common clinical route
for cell delivery to the damaged myocardium early after an
MI; however, conflicting results from clinical trials stimulated
investigations into the biodistribution of cells delivered intordiovascular Surgery c Volume 137, Number 5 1231
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Sthe coronary arteries. After intra-aortic delivery in the current
study, we observed a diffuse systemic distribution of BMSCs
that were quickly removed (approximately 90% by 48 hours
by means of bioluminescence imaging of live cells). The re-
maining cells localized mainly in the heart, lungs, and kidney,
with greater cardiac retention when the cells were implanted
into a chronic rather than an acute infarct. These data are in
agreement with results from a swine study that used radiola-
beled human peripheral blood mononuclear cells,20 whereas
a human studymonitoring the distribution of 18F-fluorodeox-
yglucose–labeled bone marrow cells showed limited radioac-
tivity in the heart, with most activity localized to the liver and
spleen.21 Intracoronary implantation appears to support only
limited cell engraftment in the heart immediately after implan-
tation. Cell delivery to the myocardium could also be con-
firmed by transfecting donor cells with thymidine kinase,
which can be tracked bymeans of noninvasive positron emis-
sion tomographic imaging.
After an MI, stem cells are mobilized from the bone mar-
row into the circulation and eventually home to damaged
myocardial tissue.22 Increasing the number of circulating
stem cells (by means of intravenous implantation) should
therefore increase the number of bone marrow cells at the
site of injury. Interestingly, Aicher and colleagues23 showed
that few radiolabeled endothelial progenitor cells homed to
the myocardium after intravenous delivery; most were re-
tained in the liver, spleen, and kidney. In the current study
intravenously implanted BMSCs homed to the heart, lungs,
and kidney, but retention in the heart was minimal at 48
hours after implantation. More than 80% of intravenously
implanted cells were removed by the host within 24 hours
after implantation, and only approximately 5% survived
by 48 hours, at which time those remaining resided almost
exclusively in the lungs.
Intramyocardial injection has been used to deliver cells
directly into the chronically infarcted myocardium during
cardiac surgery.10,24 Compared with other routes, intramyo-
cardial delivery permits accurate implantation of a larger
number of cells and precise targeting of infarct and border
regions; however, it is highly invasive. Here we delivered
the cells into the infarct by means of direct injection through
a thoracotomy. Other investigators have alternatively deliv-
ered cells directly into the heart through a catheter through
the endocardium or coronary vein. That approach avoids
the need for a thoracotomy but increases the potential for
damage to the cells as they pass through a long narrow
catheter.
We recently reported that 50% of cells escaped from the
heart within 1 hour of intramyocardial injection.25 Our cur-
rent study demonstrates a similar progressive decrease in im-
planted cell numbers: delivery into normal (sham-operated)
or acutely infarcted myocardium resulted in 50% cell sur-
vival in the heart at 2 hours (unpublished data) but greater
retention at 48 hours when the cells were injected into a ma-1232 The Journal of Thoracic and Cardiovascular Sture infarct. Although we found that some implanted cells
leaked from the implanted area into the venous system and
were retained in the lungs, intramyocardial delivery pro-
duced the greatest cell retention in the heart among the 3
approaches examined. These data are in agreement with
previous reports that intramyocardial implantation maxi-
mized cell retention in the myocardium compared with other
cell delivery routes.26
Because clinical trials have implanted cells into patients
both early and late after an MI,6-9 the timing of cell delivery
is another important consideration for cell therapy. This
study found improved cell retention after intra-aortic or intra-
myocardial implantation into hearts with mature rather than
acute infarcts, supporting the use of surgical implantation to
improve ventricular function. The increase in cell retention
might have been due to enhanced BMSC engraftment result-
ing from progressive neovascularity in the mature infarct,
and a decrease in the acute inflammatory response that might
have eliminated many of the cells in the acute infarct. The
physical integrity of the fibrous scar might also limit cell
extravasation and lead to greater cell retention in mature
infarcts, particularly during surgical delivery.
Of course, extending our current results to a clinical sce-
nario involves certain limitations. First, the rat model of
permanent LAD ligation might not directly mimic the
clinical situation in which patients receive percutaneous
reperfusion after an MI. However, ligation of a single artery
in the rats produced an extensive infarct similar to those
seen in patients with diffuse coronary artery disease who
are considered for cell transplantation or referred for coro-
nary bypass surgery. Also, because the small size of the
animals prevented intracoronary cell delivery, we used in-
tra-aortic injection to simulate intracoronary implantation.
Finally, the potential for injected BMSCs to occlude narrow
myocardial capillaries should be assessed in light of reports
that the intracoronary delivery of bone marrow–derived
cells can induce various degrees of myocardial ischemic
injury.27
Tracked by means of noninvasive molecular imaging, im-
planted BMSCs exhibited limited cardiac retention and dif-
fuse remote organ distribution within 48 hours of injection.
Future studies will focus on new techniques (for example,
gene enhancements and addition of biodegradable biomate-
rials) to improve cell retention, both to increase the efficacy
of cell therapy and to decrease any potential adverse effects
of the implanted cells.
We thank Heather McDonald Kinkaid for her assistance with
manuscript preparation and editing.
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SMATERIALS AND METHODS
Myocardial Infarction and Cell Transplantation
Female rats were anesthetized with isoflurane (2%) during mechanical
ventilation. MI was induced through a thoracotomy by means of occlusion
of the LAD. The animals were randomly separated into 6 groups. Each rat re-
ceived 33 106 transfected BMSCs (10–20 mm in diameter) in 100 mL of se-
rum-free medium at 1 of 2 time points (ie, 3 or 28 days after LAD ligation
[LAD3 and LAD28, respectively]) delivered through 1 of 3 routes (detailed
below): intra-aortic, intravenous, or intramyocardial injection. Three addi-
tional groups without LAD ligation (sham controls) also received BMSCs
by means of intra-aortic, intravenous, or intramyocardial injection (9 groups
total).
Intramyocardial implantation was performed after a thoracotomy, as pre-
viously described.E1 Cells were injected into 3 locations within the infarct to
ensure adequate distribution through the infarct and border regions. In the in-
travenous implantation group cells (in serum-freemedium)were injected into
the femoral vein through a hind-limb incision. In the intra-aortic implantation
group (injection into the ascending aortawith the distal aorta occluded to sim-
ulate intracoronary implantation), the right neck and upper sternal area were
incised to expose the common carotid artery, brachiocephalic trunk, aortic1233.e1 The Journal of Thoracic and Cardiovascular Suarch, and ascending aorta. 5-0 Silk ties were placed under the aortic arch be-
tween the left common carotid artery and the brachiocephalic trunk, under the
right common carotid artery, and under the right subclavian artery. A 24-
gauge, 0.75-inch intravenous catheter (BD Biosciences, Mississauga, On-
tario, Canada) was inserted from the common carotid artery into the aortic
root above the aortic valve. The aortic arch, the right common carotid artery,
and the right subclavian artery were occluded with the silk ties for 5 seconds
during cell injection to ensure the cells were delivered into the coronary ar-
teries. This technique delivers cells into the coronary arteries but differs
from the clinical scenario in 2 aspects: the anterior coronary artery remains
occluded (whereas it is usually opened after an infarction), and some cells re-
main in the aortic root (whereas the clinical double-balloon technique reduces
cell leakage into the aorta). The neck and upper sternal incisions were closed
by suturing the muscle layers and skin with 3-0 Vicryl sutures (Ethicon, Inc,
Somerville, NJ).
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